Today is a big day for us at Luminous Labs. We’re thrilled to announce that we’ve secured our first lead investor, Biogena Group, led by Dr. Albert Schmidbauer. This marks a huge milestone for our team and takes us one step closer to revolutionizing how the world approaches longevity and healthspan.
Biogena’s involvement goes beyond just funding—it’s a true partnership that strengthens our mission. Together, we’re on the path to delivering the world’s first fully digital supplement that targets mitochondrial health using our proprietary CellLight™ technology. With Biogena backing us, we’re ready to take our innovation to a global audience and make a real difference in how we approach healthspan.
What’s exciting about this partnership is that it’s not just about speeding up our go-to-market efforts. Biogena is deeply involved in the long-term strategic partnership, culminating in a product, which is expected to launch in early 2025. The product, which is based on our CellLight™ technology, is shaping up to be something really special. Biogena’s expertise will also help us explore new sales channels and support our transition to a subscription-based model, which fits with our broader goals of long-term growth and leadership in the longevity space.
The global longevity market is on track to reach EUR 60 billion, growing by 8.5% annually. It’s clear that people are looking for solutions that not only help them live longer but also stay healthy as they age. That’s where we come in.
At Luminous Labs, we’re committed to tackling aging at the cellular level, starting with mitochondrial health. Our CellLight™ technology helps boost cell regeneration, improve performance, and ultimately, enhance longevity. Whether in a clinical setting or used at home, our digital supplement is customized to fit each person’s unique biology. Personalized wellness isn’t just a trend—it’s where health is heading, and we’re excited to be part of that journey.
We’re also diving into an area we think doesn’t get nearly enough attention: female reproductive health. The reason for this focus is rooted in several critical factors. First, there is a significant gender health gap—women have been grossly underrepresented in medical research for far too long. Additionally, the female reproductive system is the fastest-aging organ system in the human body. By targeting this area first, we believe we can demonstrate the efficacy of our CellLight™ technology in a meaningful way.
Â
Our hope is to make a deep impact on female longevity as a starting point, with the broader goal of improving longevity for all. Our initial focus is on optimizing IVF treatments, with plans to support the natural cycle and address menopause in the future. We’ve partnered with a leading fertility clinic in Austria, and early trials are already showing promising results. This is an exciting step forward, not just for women’s health but for longevity research overall. It’s just the beginning of what we hope will be a much larger effort to improve health for everyone.
We’ve got some intriguing collaborations in the works, too. One that we’re particularly excited about is with a well-known German premium car manufacturer. Without revealing too much just yet, this partnership could see our CellLight™ technology integrated into future mobility systems—imagine cars that promote wellness while you’re on the go.Â
This is just a glimpse into the kind of innovative, far-reaching applications the technology we provide could have beyond just the health sector. The possibilities extend to various other sectors as well, including hospitality, wellness, mobility, and beyond, which goes to show how versatile our technology can be across multiple industries.
This partnership with Biogena comes at a crucial time for us. We’ve been invited back to the upcoming Longevity Investors Conference in Gstaad this Sep 24- 27, where we made waves last year as one of only seven startups selected to present—and we did it while fully bootstrapped. Now, with Biogena’s backing, we’re entering this year’s conference ready to secure the final spots in our seed round.
As our co-founder Barbara Sekulovska puts it: “There is undeniable momentum building, and we feel a sense of anticipation. We see slots in the seed round rapidly filling up, the window to be part of this pioneering journey is closing fast.”
At Luminous Labs, we’re genuinely excited about what the future holds. Biogena’s investment has given us a solid foundation to move forward with our mission, and we’re gearing up for our CellLight™-powered product set to launch in 2025.
Our goal has always been clear: using light and technology to improve health and longevity. But it’s more than just a vision—it’s something we’re actively building. The excitement isn’t just about what’s on paper; it’s about the real-world impact we’re hoping to make, from supporting cell health to exploring new ways to integrate wellness into everyday life.
We’re just getting started, and we’re thrilled to have you with us on this journey. As we prepare to close our seed round at the upcoming conference, we invite you to be a part of our groundbreaking venture. Reach out to us at partner@luminousred.com for our pitch deck and explore how you can invest in a future that’s bright—literally and figuratively. Be a key player in the future of health technology!
Designing with love by lighting experts in Austria, Europe
100-day money-back guarantee
Global express shipping
Discount Applied Successfully!
Your savings have been added to the cart.
